Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
HUNAN FANGSHENG PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 11.02 CNY | -1.69% | -1.43% | +37.58% | |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions on site
| Sales 2023 * | 1,930 M 271 M | Sales 2024 * | 2,371 M 333 M | Capitalization | 4,846 M 680 M |
|---|---|---|---|---|---|
| Net income 2023 * | 165 M 23.16 M | Net income 2024 * | 224 M 31.44 M | EV / Sales 2023 * | 2,51x |
| Net cash position 2023 * | - 0 | Net cash position 2024 * | - 0 | EV / Sales 2024 * | 2,04x |
| P/E ratio 2023 * | 29,4x | P/E ratio 2024 * | 21,8x | Employees | 1,600 |
| Yield 2023 * | 1,27% | Yield 2024 * | 1,81% | Free-Float | 60.82% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.69% | ||
| 1 week | -1.43% | ||
| Current month | +0.27% | ||
| 1 month | +5.15% | ||
| 3 months | +19.26% | ||
| 6 months | -24.68% | ||
| Current year | +37.58% |
1 week
10.84
12.00
1 month
10.6712.00
Current year
8.1914.73
1 year
7.2814.73
3 years
4.7714.73
5 years
4.5015.07
10 years
4.5021.70
| Managers | Title | Age | Since |
|---|---|---|---|
Xiao Li Zhou
CEO | Chief Executive Officer | 50 | - |
Han Qing Xiao
CEO | Chief Executive Officer | 49 | - |
| 42 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chuan Long Fang
CHM | Chairman | 58 | - |
Xiong Yuan
BRD | Director/Board Member | 58 | 2021 |
Zhang Lin Liu
BRD | Director/Board Member | 67 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-11-29 | 11.02 | -1.69% | 5,669,402 |
| 23-11-28 | 11.21 | -0.44% | 10,152,300 |
| 23-11-27 | 11.26 | -3.10% | 13,409,970 |
| 23-11-24 | 11.62 | +2.20% | 24,861,400 |
| 23-11-23 | 11.37 | +1.70% | 8,615,867 |
End-of-day quote Shanghai Stock Exchange, November 28, 2023
More quotes
Hunan FangshengPharmaceutical Co., Ltd. is a China-based company principally engaged in the research, development, production and sale of cardiovascular medicine, orthopedic medicine, pediatric medicine, gynecological medicine and anti-infective medicine. The Company's main products include Xuesaitong Dispersible Tablets, Xuesaitong Tablets, Tenghuang Jiangu Tablets, Dieda Huoxue Capsules, Lysine Dimension B12 Granules, Cefixoxime Tablets and Jinying Capsules. The Company distributes its products primarily in domestic market.
Sector
Pharmaceuticals
Calendar
2024-04-25
- Q1 2024 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
-
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
11.02CNY
Average target price
16.38CNY
Spread / Average Target
+48.64%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. (M$) | |
|---|---|---|
| +37.58% | 690 M $ | |
| +20.93% | 34 297 M $ | |
| +32.61% | 20 717 M $ | |
| 0.00% | 12 784 M $ | |
| +11.48% | 11 549 M $ | |
| -12.31% | 8 876 M $ | |
| +52.34% | 7 649 M $ | |
| -0.05% | 6 788 M $ | |
| -8.87% | 5 726 M $ | |
| +2.34% | 5 130 M $ |
